{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:27:01Z","timestamp":1758968821349},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2011,5,10]],"date-time":"2011-05-10T00:00:00Z","timestamp":1304985600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2011,12]]},"DOI":"10.1007\/s00280-011-1657-1","type":"journal-article","created":{"date-parts":[[2011,5,9]],"date-time":"2011-05-09T05:57:43Z","timestamp":1304920663000},"page":"1595-1602","source":"Crossref","is-referenced-by-count":26,"title":["A phase II trial of gemcitabine and capecitabine in patients with unresectable or metastatic gallbladder cancer or cholangiocarcinoma: Southwest Oncology Group study S0202"],"prefix":"10.1007","volume":"68","author":[{"given":"Syma","family":"Iqbal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathryn","family":"Rankin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heinz-Josef","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philip J.","family":"Gold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed A.","family":"Ahmad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anthony B.","family":"El-Khoueiry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Messino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall F.","family":"Holcombe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Charles D.","family":"Blanke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,5,10]]},"reference":[{"key":"1657_CR1","unstructured":"American Cancer Society (2010). Cancer facts & figures. American Cancer Society, Atlanta"},{"key":"1657_CR2","doi-asserted-by":"crossref","unstructured":"Serra I, Calvo A, Baez S et al (1996) Risk factors for gallbladder cancer. An international collaborative case-control study. Cancer 78:1515\u20131517","DOI":"10.1002\/(SICI)1097-0142(19961001)78:7<1515::AID-CNCR21>3.0.CO;2-1"},{"key":"1657_CR3","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1002\/1097-0142(19840915)54:6<965::AID-CNCR2820540603>3.0.CO;2-X","volume":"54","author":"G Falkson","year":"1984","unstructured":"Falkson G, MacIntyre JM, Moertel CG (1984) Eastern Cooperative Oncology Group experience with chemotherapy for inoperable gallbladder and bile duct cancer. Cancer 54:965\u2013969","journal-title":"Cancer"},{"key":"1657_CR4","unstructured":"Takada T, Kato H, Matsushiro T et al (1996) Prospective randomized trial comparing 1\/2 FAM (5-fluorouracil (5-FU)\u00a0+\u00a0adriamycin\u00a0+\u00a0mitomycin C) versus palliative therapy for the treatment of unresectable pancreatic and biliary tract carcinomas (the 2nd trial in non-resectable patients). Japanese Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract. Gan To Kagaku Ryoho 23:707\u2013714"},{"key":"1657_CR5","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1097\/00000421-199406000-00008","volume":"17","author":"M Kajanti","year":"1994","unstructured":"Kajanti M, Pyrhonen S (1994) Epirubicin-sequential methotrexate-5-fluorouracil-leucovorin treatment in advanced cancer of the extrahepatic biliary system. A phase II study. Am J Clin Oncol 17:223\u2013226","journal-title":"Am J Clin Oncol"},{"key":"1657_CR6","doi-asserted-by":"crossref","unstructured":"Patt YZ, Jones DV Jr, Hoque A et al (1996) Phase II trial of intravenous flourouracil and subcutaneous interferon alfa-2b for biliary tract cancer. J Clin Oncol 14:2311\u20132315","DOI":"10.1200\/JCO.1996.14.8.2311"},{"key":"1657_CR7","doi-asserted-by":"crossref","unstructured":"Sanz-Altamira PM, Ferrante K, Jenkins RL et al (1998) A phase II trial of 5-fluorouracil, leucovorin, and carboplatin in patients with unresectable biliary tree carcinoma. Cancer 82:2321\u20132325","DOI":"10.1002\/(SICI)1097-0142(19980615)82:12<2321::AID-CNCR4>3.0.CO;2-V"},{"key":"1657_CR8","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/00001813-200010000-00006","volume":"11","author":"F Verderame","year":"2000","unstructured":"Verderame F, Mandina P, Abruzzo F et al (2000) Biliary tract cancer: our experience with gemcitabine treatment. Anticancer Drugs 11:707\u2013708","journal-title":"Anticancer Drugs"},{"key":"1657_CR9","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1002\/(SICI)1097-0142(19980215)82:4<639::AID-CNCR4>3.0.CO;2-G","volume":"82","author":"MP Castro","year":"1998","unstructured":"Castro MP (1998) Efficacy of gemcitabine in the treatment of patients with gallbladder carcinoma: a case report. Cancer 82:639\u2013641","journal-title":"Cancer"},{"key":"1657_CR10","doi-asserted-by":"crossref","unstructured":"Eng C, Ramanathan RK, Wong MK et al (2004) A phase II trial of fixed dose rate gemcitabine in patients with advanced biliary tree carcinoma. Am J Clin Oncol 27:565\u2013569","DOI":"10.1097\/01.coc.0000135924.94955.16"},{"key":"1657_CR11","doi-asserted-by":"crossref","unstructured":"Valle J, Wasan H, Palmer DH et al (2010) Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med 362:1273\u20131281","DOI":"10.1056\/NEJMoa0908721"},{"key":"1657_CR12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","volume":"96","author":"F Eckel","year":"2007","unstructured":"Eckel F, Schmid RM (2007) Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials. Br J Cancer 96:896\u2013902","journal-title":"Br J Cancer"},{"key":"1657_CR13","unstructured":"Braakhuis BJ, Ruiz van Haperen VW, Boven E et al (1995) Schedule-dependent antitumor effect of gemcitabine in in vivo model system. Semin Oncol 22:42\u201346"},{"key":"1657_CR14","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1200\/JCO.2003.09.140","volume":"21","author":"M Tempero","year":"2003","unstructured":"Tempero M, Plunkett W, Ruiz Van Haperen V et al (2003) Randomized phase II comparison of dose-intense gemcitabine: thirty-minute infusion and fixed dose rate infusion in patients with pancreatic adenocarcinoma. J Clin Oncol 21:3402\u20133408","journal-title":"J Clin Oncol"},{"key":"1657_CR15","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/00008571-200405000-00007","volume":"14","author":"MV Mandola","year":"2004","unstructured":"Mandola MV, Stoehlmacher J, Zhang W et al (2004) A 6\u00a0bp polymorphism in the thymidylate synthase gene causes message instability and is associated with decreased intratumoral TS mRNA levels. Pharmacogenetics 14:319\u2013327","journal-title":"Pharmacogenetics"},{"key":"1657_CR16","doi-asserted-by":"crossref","unstructured":"Lurje G, Zhang W, Yang D et al (2008) Thymidylate synthase haplotype is associated with tumor recurrence in stage II and stage III colon cancer. Pharmacogenet Genomics 18:161\u2013168","DOI":"10.1097\/FPC.0b013e3282f4aea6"},{"key":"1657_CR17","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1002\/cncr.22902","volume":"110","author":"RP Riechelmann","year":"2007","unstructured":"Riechelmann RP, Townsley CA, Chin SN et al (2007) Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer. Cancer 110:1307\u20131312","journal-title":"Cancer"},{"key":"1657_CR18","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1002\/cncr.21591","volume":"104","author":"JY Cho","year":"2005","unstructured":"Cho JY, Paik YH, Chang YS et al (2005) Capecitabine combined with gemcitabine (CapGem) as first-line treatment in patients with advanced\/metastatic biliary tract carcinoma. Cancer 104:2753\u20132758","journal-title":"Cancer"},{"key":"1657_CR19","doi-asserted-by":"crossref","first-page":"3202","DOI":"10.1245\/s10434-007-9539-9","volume":"14","author":"RV Iyer","year":"2007","unstructured":"Iyer RV, Gibbs J, Kuvshinoff B et al (2007) A phase II study of gemcitabine and capecitabine in advanced cholangiocarcinoma and carcinoma of the gallbladder: a single-institution prospective study. Ann Surg Oncol 14:3202\u20133209","journal-title":"Ann Surg Oncol"},{"key":"1657_CR20","doi-asserted-by":"crossref","unstructured":"Santini D, Vincenzi B, Vasile E et al (2009) Fixed dose rate (FDR) gemcitabine (G) and capecitabine (C) in patients with metastatic biliary tract cancer (BTC): final results of phase II trial. Abstract # e15510. Proceedings of the American Society of Clinical Oncology","DOI":"10.1200\/jco.2009.27.15_suppl.e15510"},{"key":"1657_CR21","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1002\/cncr.21741","volume":"106","author":"ST Kim","year":"2006","unstructured":"Kim ST, Park JO, Lee J et al (2006) A phase II study of gemcitabine and cisplatin in advanced biliary tract cancer. Cancer 106:1339\u20131346","journal-title":"Cancer"},{"key":"1657_CR22","first-page":"110","volume":"5","author":"PK Julka","year":"2006","unstructured":"Julka PK, Puri T, Rath GK (2006) A phase II study of gemcitabine and carboplatin combination chemotherapy in gallbladder carcinoma. Hepatobiliary Pancreat Dis Int 5:110\u2013114","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1657_CR23","doi-asserted-by":"crossref","unstructured":"Andr\u00e9 T, Reyes-Vidal JM, Fartoux L et al (2006) An international multicenter phase II trial of gemcitabine and oxaliplatin (GEMOX) in patients with advanced biliary tract cancer. J Clin Oncol. ASCO annual meeting proceedings part I, vol 24, no. 18S (June 20 Supplement), p 4135","DOI":"10.1200\/jco.2006.24.18_suppl.4135"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1657-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-011-1657-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-011-1657-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,22]],"date-time":"2021-11-22T22:54:06Z","timestamp":1637621646000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-011-1657-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,5,10]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2011,12]]}},"alternative-id":["1657"],"URL":"https:\/\/doi.org\/10.1007\/s00280-011-1657-1","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,5,10]]}}}